Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

IRON

Disc Medicine Inc

May 21 • 04:00PM ET

31.26

Dollar change -1.11
Percentage change -3.43	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB LABU IWO DWAS SCHA VHT VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.39	Insider Own	47.75%	Shs Outstand	24.72M	Perf Week	-1.82%
Market Cap	772.75M	Forward P/E	-	EPS next Y	-5.38	Insider Trans	-13.26%	Shs Float	12.92M	Perf Month	15.86%
Income	-80.60M	PEG	-	EPS next Q	-1.16	Inst Own	61.40%	Short Float	12.94%	Perf Quarter	-51.80%
Sales	0.00M	P/S	-	EPS this Y	-35.20%	Inst Trans	4.10%	Short Ratio	3.36	Perf Half Y	-39.82%
Book/sh	13.69	P/B	2.28	EPS next Y	-16.25%	ROA	-26.96%	Short Interest	1.67M	Perf Year	-7.51%
Cash/sh	13.86	P/C	2.26	EPS next 5Y	-	ROE	-28.23%	52W Range	25.60 - 77.60	Perf YTD	-45.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-23.75%	52W High	-59.72%	Beta	0.49
Dividend TTM	-	Quick Ratio	23.70	Sales past 5Y	0.00%	Gross Margin	-	52W Low	22.11%	ATR (14)	1.92
Dividend Ex-Date	-	Current Ratio	23.70	EPS Y/Y TTM	29.70%	Oper. Margin	0.00%	RSI (14)	43.47	Volatility	4.39% 5.26%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	57.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	9.62%	Payout	-	Rel Volume	0.81	Prev Close	32.37
Sales Surprise	-	EPS Surprise	-8.11%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	497.14K	Price	31.26
SMA20	5.31%	SMA50	-20.61%	SMA200	-39.55%	Trades		Volume	401,739	Change	-3.43%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform	$40
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $65
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy	$50 → $75
Jun-07-23	Initiated	H.C. Wainwright	Buy	$55
May-17-23	Initiated	Raymond James	Outperform	$50
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight	$45
Apr-21-23	Initiated	Stifel	Buy	$37
Apr-20-23	Initiated	Morgan Stanley	Overweight	$37
Mar-23-23	Initiated	BMO Capital Markets	Outperform	$40
Feb-28-23	Initiated	SVB Securities	Outperform	$36

May-14-24 10:30AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire)
May-13-24 08:00AM	Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-11-24 05:31AM	Disc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:54PM	IRON Stock Earnings: Disc Medicine Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
02:24PM	Loading…
Apr-02-24 02:24PM	Disc Medicine (IRON) Down on Mixed Results From AURORA Study (Zacks) -6.36%
Apr-01-24 04:19PM	Disc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity Study (Investor's Business Daily) -45.05%
08:00AM	Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-23-24 05:31AM	Disc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal Performance (GuruFocus.com)
Mar-21-24 08:00AM	Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.52%
Mar-06-24 04:30PM	Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-26-24 08:30AM	Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer (GlobeNewswire)
Feb-20-24 08:30AM	Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease (GlobeNewswire)
Feb-09-24 09:00AM	Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera (GlobeNewswire)
Feb-07-24 08:00AM	Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer (GlobeNewswire)
05:00PM	Loading…
Jan-03-24 05:00PM	Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:30PM	Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board (GlobeNewswire)
Dec-15-23 03:01PM	Insider Sell Alert: Director William White Sells 33,511 Shares of Disc Medicine Inc (IRON) (GuruFocus.com)
Dec-11-23 08:30PM	Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
12:00PM	Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-08-23 07:06AM	Insider Sell Alert: CFO Joanne Bryce Sells 2,541 Shares of Disc Medicine Inc (IRON) (GuruFocus.com) +5.98%
Nov-14-23 04:44PM	Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin (GlobeNewswire)
Nov-13-23 09:55AM	How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17% (Zacks)
Nov-09-23 09:34AM	Disc Medicine Inc (IRON) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
08:30AM	Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates (GlobeNewswire)
Oct-23-23 09:15AM	Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce (GlobeNewswire)
Oct-03-23 08:30AM	Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers (GlobeNewswire)
04:30PM	Loading…
Sep-20-23 04:30PM	Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera (GlobeNewswire)
Aug-30-23 04:15PM	Disc Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 11:20AM	Stock Screen Finds These Growth Stocks Outperforming The S&P 500 (Investor's Business Daily)
Aug-11-23 08:50AM	Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why (Zacks)
08:00AM	Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 09:00AM	Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA) (GlobeNewswire)
Jul-25-23 09:55AM	Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-22-23 04:15PM	Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-20-23 07:33PM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +7.20%
Jun-13-23 10:39PM	Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-12-23 04:00PM	Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.92%
01:59AM	4 big analyst picks: Adobe a buy on AI hopes, says Wells Fargo (Investing.com)
Jun-09-23 04:13PM	Why Perfectly Rated Disc Medicine, With A 287% Move This Year, Just Put Up Another Big Gain (Investor's Business Daily) +15.76%
07:00AM	Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress (GlobeNewswire)
Jun-01-23 03:10PM	Why Shares of Disc Medicine Opco Climbed This Week (Motley Fool) +7.06%
May-31-23 04:00PM	Disc Medicine to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +12.01%
May-15-23 07:00AM	Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-11-23 10:15AM	Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress (GlobeNewswire)
May-10-23 10:23AM	Is a Surprise Coming for Disc Medicine (IRON) This Earnings Season? (Zacks) +5.24%
May-05-23 08:50AM	Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
May-04-23 12:00PM	Disc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should Know (Zacks)
Apr-28-23 05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
Apr-21-23 08:30AM	Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +11.57%
Apr-19-23 08:50AM	Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why (Zacks)
Apr-13-23 11:00AM	Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP) (GlobeNewswire)
Mar-31-23 07:00AM	Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-30-23 07:05AM	Disc Medicine Opco Inc (NASDAQ:IRON) most popular amongst private equity firms who own 48% of the shares, institutions hold 21% (Simply Wall St.)
Mar-21-23 07:00AM	Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA) (GlobeNewswire)
Feb-16-23 08:00AM	Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia (GlobeNewswire)
Feb-14-23 06:30AM	Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs (GlobeNewswire)
Feb-08-23 04:00PM	Disc Medicine to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 07:00AM	Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis (GlobeNewswire)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
White William Richard	Director	May 01 '24	Option Exercise	9.86	201	1,982	201	May 03 04:05 PM
White William Richard	Director	May 01 '24	Sale	28.63	201	5,755	0	May 03 04:05 PM
White William Richard	Director	Apr 11 '24	Option Exercise	4.91	2,560	12,581	2,560	Apr 15 06:27 PM
White William Richard	Director	Apr 11 '24	Sale	31.80	2,560	81,407	0	Apr 15 06:27 PM
Savage William Jacob	Chief Medical Officer	Apr 10 '24	Option Exercise	2.65	21,870	57,956	43,405	Apr 11 05:02 PM
Bitterman Kevin	Director	Mar 05 '24	Sale	73.50	26,157	1,922,540	677,503	Mar 07 04:40 PM
Bitterman Kevin	Director	Jan 23 '24	Sale	67.65	102,500	6,934,125	198,326	Jan 25 04:33 PM
Atlas Venture Fund X, L.P.	10% Owner	Jan 23 '24	Sale	67.65	102,500	6,934,125	198,326	Jan 25 04:31 PM
Atlas Venture Fund X, L.P.	10% Owner	Jan 23 '24	Sale	67.65	47,500	3,213,375	1,402,186	Jan 25 04:31 PM
Atlas Venture Fund X, L.P.	10% Owner	Jan 10 '24	Sale	64.00	30,000	1,920,000	1,449,686	Jan 12 05:12 PM
Bitterman Kevin	Director	Jan 10 '24	Sale	64.00	20,000	1,280,000	786,160	Jan 12 05:12 PM
Atlas Venture Fund X, L.P.	10% Owner	Jan 10 '24	Sale	64.00	20,000	1,280,000	786,160	Jan 12 05:12 PM
Quisel John D	Chief Executive Officer	Dec 29 '23	Option Exercise	1.01	2,700	2,727	2,700	Jan 03 04:05 PM
Bryce Joanne	Chief Financial Officer	Dec 27 '23	Option Exercise	9.86	3,000	29,580	5,500	Dec 29 04:15 PM
Ashiya Mona	Director	Dec 18 '23	Option Exercise	38.00	1,724	65,512	1,724	Dec 20 06:16 PM
ORBIMED ADVISORS LLC	Director	Dec 18 '23	Option Exercise	38.00	1,724	65,512	1,724	Dec 20 06:28 PM
Ashiya Mona	Director	Dec 18 '23	Sale	59.24	1,724	102,130	0	Dec 20 06:16 PM
ORBIMED ADVISORS LLC	Director	Dec 18 '23	Sale	59.24	1,724	102,130	0	Dec 20 06:28 PM
ORBIMED ADVISORS LLC	Director	Dec 14 '23	Sale	56.75	433,200	24,584,100	224,405	Dec 15 06:04 PM
Ashiya Mona	Director	Dec 14 '23	Sale	56.75	433,200	24,584,100	224,405	Dec 15 06:09 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 14 '23	Sale	58.28	30,825	1,796,437	1,479,686	Dec 14 08:13 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 14 '23	Sale	58.28	20,549	1,197,567	806,160	Dec 14 08:13 PM
Bitterman Kevin	Director	Dec 14 '23	Sale	58.28	20,549	1,197,567	806,160	Dec 14 08:14 PM
ORBIMED ADVISORS LLC	Director	Dec 14 '23	Sale	57.73	200	11,546	727,807	Dec 14 05:44 PM
Ashiya Mona	Director	Dec 14 '23	Sale	57.73	200	11,546	727,807	Dec 14 05:40 PM
Ashiya Mona	Director	Dec 13 '23	Sale	58.56	106,700	6,248,352	281,505	Dec 14 05:40 PM
ORBIMED ADVISORS LLC	Director	Dec 13 '23	Sale	58.56	106,700	6,248,352	281,505	Dec 14 05:44 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 13 '23	Sale	60.00	5,323	319,357	1,510,511	Dec 14 08:13 PM
Bitterman Kevin	Director	Dec 13 '23	Sale	60.00	3,548	212,865	826,709	Dec 14 08:14 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 13 '23	Sale	60.00	3,548	212,865	826,709	Dec 14 08:13 PM
White William Richard	Director	Dec 12 '23	Option Exercise	6.08	33,511	203,883	33,511	Dec 14 04:15 PM
Bryce Joanne	Chief Financial Officer	Dec 12 '23	Option Exercise	2.65	2,500	6,625	5,000	Dec 14 04:15 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 12 '23	Sale	62.80	77,951	4,895,032	1,515,834	Dec 14 08:13 PM
Atlas Venture Fund X, L.P.	10% Owner	Dec 12 '23	Sale	62.80	51,967	3,263,328	830,257	Dec 14 08:13 PM
Bitterman Kevin	Director	Dec 12 '23	Sale	62.80	51,967	3,263,328	830,257	Dec 14 08:14 PM
White William Richard	Director	Dec 12 '23	Sale	63.21	33,511	2,118,239	0	Dec 14 04:15 PM
ORBIMED ADVISORS LLC	Director	Dec 12 '23	Sale	60.16	27,300	1,642,368	295,605	Dec 14 05:44 PM
Ashiya Mona	Director	Dec 12 '23	Sale	60.16	27,300	1,642,368	295,605	Dec 14 05:40 PM
Bryce Joanne	Chief Financial Officer	Dec 12 '23	Sale	65.22	2,500	163,062	2,500	Dec 14 04:15 PM
Bryce Joanne	Chief Financial Officer	Dec 05 '23	Option Exercise	1.01	1,281	1,294	5,041	Dec 07 04:15 PM
Bryce Joanne	Chief Financial Officer	Dec 05 '23	Sale	56.00	2,541	142,299	2,500	Dec 07 04:15 PM
Khara Rahul	General Counsel	Nov 22 '23	Option Exercise	14.69	10,000	146,900	10,000	Nov 27 04:15 PM
Khara Rahul	General Counsel	Nov 22 '23	Sale	51.73	10,000	517,333	0	Nov 27 04:15 PM
Khara Rahul	General Counsel	Nov 14 '23	Option Exercise	14.69	4,900	71,981	4,900	Nov 15 05:00 PM
Khara Rahul	General Counsel	Nov 14 '23	Sale	50.61	4,900	248,012	0	Nov 15 05:00 PM
Khara Rahul	General Counsel	Nov 03 '23	Option Exercise	14.69	100	1,469	100	Nov 07 06:22 PM
Khara Rahul	General Counsel	Nov 03 '23	Sale	50.00	100	5,000	0	Nov 07 06:22 PM
Atlas Venture Fund X, L.P.	10% Owner	Sep 16 '23	Sale	53.22	2,115	112,560	1,593,785	Sep 18 04:59 PM
Atlas Venture Fund X, L.P.	10% Owner	Sep 15 '23	Sale	53.16	260,894	13,869,125	1,595,900	Sep 18 04:59 PM
Atlas Venture Fund X, L.P.	10% Owner	Sep 14 '23	Sale	53.05	94,440	5,010,042	1,856,794	Sep 18 04:59 PM
Bryce Joanne	Chief Financial Officer	Sep 11 '23	Option Exercise	9.86	2,500	24,650	3,760	Sep 13 04:15 PM
Bryce Joanne	Chief Financial Officer	Sep 01 '23	Option Exercise	2.65	1,000	2,650	2,260	Sep 05 04:16 PM
Bryce Joanne	Chief Financial Officer	Sep 01 '23	Sale	52.99	1,000	52,990	1,260	Sep 05 04:16 PM
Savage William Jacob	Chief Medical Officer	Aug 21 '23	Option Exercise	2.65	3,000	7,950	3,000	Aug 22 04:06 PM
Atlas Venture Fund X, L.P.	10% Owner	Aug 15 '23	Sale	52.40	111,069	5,820,016	1,951,234	Aug 16 06:55 PM
Bitterman Kevin	Director	Aug 15 '23	Sale	52.40	72,931	3,821,584	882,224	Aug 17 04:13 PM
Atlas Venture Fund X, L.P.	10% Owner	Aug 15 '23	Sale	52.40	72,931	3,821,584	882,224	Aug 16 06:55 PM
Savage William Jacob	Chief Medical Officer	Aug 15 '23	Sale	52.95	7,672	406,235	0	Aug 16 04:15 PM
Atlas Venture Fund X, L.P.	10% Owner	Aug 14 '23	Sale	52.59	175,000	9,203,600	2,062,303	Aug 16 06:55 PM
Savage William Jacob	Chief Medical Officer	Aug 09 '23	Sale	49.83	8,269	412,064	7,672	Aug 11 04:15 PM
Bryce Joanne	Chief Financial Officer	Aug 01 '23	Option Exercise	1.01	4,521	4,566	5,781	Aug 03 04:18 PM
Bryce Joanne	Chief Financial Officer	Aug 01 '23	Sale	49.91	4,521	225,633	1,260	Aug 03 04:18 PM
MacDonald Brian Richard	Chief Innovation Officer	Jun 30 '23	Sale	45.05	4,324	194,778	12,876	Jun 30 06:29 PM
MacDonald Brian Richard	Chief Innovation Officer	Jun 29 '23	Sale	45.79	5,100	233,509	17,200	Jun 30 06:29 PM
Bryce Joanne	Chief Financial Officer	Jun 28 '23	Option Exercise	1.01	7,880	7,959	11,332	Jun 30 04:49 PM
Novo Holdings A/S	10% Owner	Jun 28 '23	Sale	46.10	1,250,000	57,625,000	1,090,772	Jun 28 05:04 PM
Bryce Joanne	Chief Financial Officer	Jun 28 '23	Sale	49.95	10,072	503,114	1,260	Jun 30 04:49 PM
MacDonald Brian Richard	Chief Innovation Officer	Jun 28 '23	Sale	49.96	5,100	254,795	22,300	Jun 30 06:29 PM
Savage William Jacob	Chief Medical Officer	Jun 28 '23	Sale	49.98	4,384	219,114	15,941	Jun 30 04:12 PM

Open in Screener

AKRO

Akero Therapeutics Inc

May 21 • 04:00PM ET

20.24

Dollar change +0.10
Percentage change 0.50	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

AKRO Akero Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IBB SCHA SURI VTWO LABU VHT

Index	RUT	P/E	-	EPS (ttm)	-3.20	Insider Own	15.97%	Shs Outstand	69.15M	Perf Week	-0.30%
Market Cap	1.40B	Forward P/E	-	EPS next Y	-4.22	Insider Trans	0.49%	Shs Float	58.11M	Perf Month	-2.65%
Income	-179.27M	PEG	-	EPS next Q	-0.89	Inst Own	98.05%	Short Float	14.80%	Perf Quarter	-15.81%
Sales	0.00M	P/S	-	EPS this Y	-33.39%	Inst Trans	15.70%	Short Ratio	6.97	Perf Half Y	29.58%
Book/sh	12.24	P/B	1.65	EPS next Y	-9.41%	ROA	-28.43%	Short Interest	8.60M	Perf Year	-55.61%
Cash/sh	13.07	P/C	1.55	EPS next 5Y	-14.60%	ROE	-31.11%	52W Range	11.25 - 58.38	Perf YTD	-13.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.03%	ROI	-20.33%	52W High	-65.33%	Beta	-0.30
Dividend TTM	-	Quick Ratio	30.12	Sales past 5Y	0.00%	Gross Margin	-	52W Low	79.91%	ATR (14)	1.17
Dividend Ex-Date	-	Current Ratio	30.12	EPS Y/Y TTM	-17.00%	Oper. Margin	0.00%	RSI (14)	44.95	Volatility	4.16% 5.67%
Employees	56	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.20	Target Price	46.78
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-63.47%	Payout	-	Rel Volume	0.35	Prev Close	20.14
Sales Surprise	-	EPS Surprise	0.24%	Sales Q/Q	-	Earnings	May 10 BMO	Avg Volume	1.23M	Price	20.24
SMA20	-0.61%	SMA50	-10.59%	SMA200	-24.92%	Trades		Volume	434,478	Change	0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Resumed	BofA Securities	Neutral	$30
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28
Jul-15-19	Initiated	Evercore ISI	Outperform	$35

Show Previous Ratings

May-15-24 09:26AM	Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating (MT Newswires)
May-12-24 09:01PM	Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ... (GuruFocus.com)
May-10-24 01:54PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.53%
07:45AM	Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 (MT Newswires)
07:00AM	Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
May-08-24 07:00AM	Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference (GlobeNewswire)
Apr-30-24 08:00AM	Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
12:58PM	AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-08-24 04:02PM	Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Mar-07-24 04:01PM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology (GlobeNewswire)
Mar-06-24 11:54PM	President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO) (GuruFocus.com)
Mar-05-24 09:13PM	Akero Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
02:12PM	Loading…
02:12PM	Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study (Zacks)
Mar-04-24 04:21PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +11.72%
04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily)
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
11:59AM	Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market (Barrons.com)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
06:22AM	UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients (Reuters)
06:09AM	Akero's lead drug helps improve scarring in fatty liver disease patients (Reuters)
06:00AM	Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study (GlobeNewswire)
04:00AM	Akero strengthens MASH drugs case with new study data (BioPharma Dive)
Mar-01-24 09:55AM	Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know (Zacks)
Feb-29-24 08:00AM	Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH (GlobeNewswire)
07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-06-24 10:48AM	Cramer's Stop Trading: Akero Therapeutics (CNBC TV) -12.25%
Feb-05-24 09:55AM	Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now (Zacks)
09:40AM	Loading…
Jan-30-24 09:40AM	Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.22%
Jan-03-24 08:15AM	Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.41%
Dec-18-23 07:00AM	Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program (GlobeNewswire)
Dec-13-23 03:06AM	Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ... (GuruFocus.com)
Dec-05-23 01:34PM	12 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
12:36PM	Hedge Fund and Insider Trading News: Jeff Ubben, Bill Ackman, Saba Capital Management, Akero Therapeutics Inc (AKRO), Verizon Communications Inc. (VZ) and More (Insider Monkey)
Nov-14-23 07:21PM	Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-13-23 07:00AM	Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-23 08:57AM	Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Nov-08-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in November (GlobeNewswire)
Oct-17-23 04:05PM	Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference (GlobeNewswire)
Oct-12-23 04:38PM	Why Akero Therapeutics Shares Are Slumping This Week (Motley Fool)
08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-11-23 05:35PM	Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward (Benzinga) -17.13%
11:11AM	Akero (AKRO) Slumps 63% on Mixed Results From NASH Study (Zacks)
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -62.61%
04:03PM	Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio (Investor's Business Daily)
12:10PM	PepsiCo, Palantir rise; Neogen, Akero Therapeutics fall, Tuesday, 10/10/2023 (Associated Press Finance)
11:44AM	Why Akero Therapeutics Stock Is Crashing Today (Motley Fool)
10:37AM	Akero Therapeutics, Palantir, Hyatt Hotels: Trending tickers (Yahoo Finance Video)
09:29AM	Why Is Akero Therapeutics (AKRO) Stock Down 58% Today? (InvestorPlace)
07:15AM	Akero's drug for fatty liver disease misses main trial goal (Reuters)
07:00AM	Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins (GlobeNewswire)
Oct-09-23 04:05PM	Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH (GlobeNewswire)
Oct-05-23 07:01AM	Insider Sell: Akero Therapeutics Inc CEO Andrew Cheng Sells 25,000 Shares (GuruFocus.com)
Oct-04-23 08:00AM	Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-14-23 07:56AM	Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA (Zacks)
Aug-31-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in September (GlobeNewswire)
Aug-28-23 07:00AM	Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023 (GlobeNewswire)
Aug-11-23 06:00AM	Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +6.59%
Jul-11-23 09:02AM	Infinity Pharma (INFI) Stock Up on Advancing Cancer Study (Zacks)
Jul-10-23 09:32AM	Viking Therapeutics (VKTX) Surges 64% Year to Date: Here's Why (Zacks)
09:29AM	Sotherly Hotels' (SOHO) Q2 Operating Trend Reflects Solid Demand (Zacks)
08:58AM	Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study (Zacks)
Jul-07-23 08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks)
Jul-03-23 11:20AM	Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune (Zacks)
10:25AM	Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date (Zacks)
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-29-23 10:04AM	Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe (Zacks)
09:59AM	Axsome (AXSM) Down on Public Offering of Common Stock (Zacks)
09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-28-23 10:53AM	Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug (Zacks)
Jun-27-23 01:47PM	Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks) -9.17%
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
10:36AM	Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate (Zacks)
08:50AM	Recent Price Trend in Akero Therapeutics, Inc. (AKRO) is Your Friend, Here's Why (Zacks)
08:21AM	Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata (Zacks)
06:41AM	Daily Vickers Top Buyers & Sellers for 06/26/2023 (Argus Research)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks)
09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
07:00AM	Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology (GlobeNewswire)
Jun-22-23 09:18AM	Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate (Zacks)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
10:46AM	Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal (Zacks)
Jun-20-23 08:54AM	Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly (Zacks)
Jun-19-23 10:28AM	Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS (Zacks)
10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:17PM	Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer (Zacks)
11:48AM	Recursion (RXRX) Up on Completing REC-994 Study Enrollment (Zacks)
09:26AM	Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
09:40AM	Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year? (Zacks)

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Jonathan	Chief Operating Officer	May 01 '24	Sale	20.15	5,000	100,750	258,306	May 02 09:07 PM
Young Jonathan	Chief Operating Officer	Apr 01 '24	Sale	24.38	5,000	121,913	263,306	Apr 03 06:55 PM
Cheng Andrew	President and CEO	Mar 13 '24	Sale	28.33	1,969	55,782	589,447	Mar 15 04:43 PM
White William Richard	Chief Financial Officer	Mar 13 '24	Sale	28.33	724	20,511	49,630	Mar 15 04:44 PM
Yale Catriona	Chief Development Officer	Mar 13 '24	Sale	28.33	723	20,483	77,692	Mar 15 04:45 PM
Young Jonathan	Chief Operating Officer	Mar 13 '24	Sale	28.33	651	18,443	268,306	Mar 15 04:42 PM
Rolph Timothy	Chief Scientific Officer	Mar 13 '24	Sale	28.33	619	17,536	182,558	Mar 15 04:42 PM
Cheng Andrew	President and CEO	Mar 04 '24	Option Exercise	17.17	75,000	1,288,062	666,416	Mar 06 08:14 PM
Yale Catriona	Chief Development Officer	Mar 04 '24	Option Exercise	13.96	20,646	288,124	99,061	Mar 06 08:13 PM
Cheng Andrew	President and CEO	Mar 04 '24	Sale	32.87	75,000	2,465,063	591,416	Mar 06 08:14 PM
Yale Catriona	Chief Development Officer	Mar 04 '24	Sale	35.49	20,646	732,727	78,415	Mar 06 08:13 PM
Young Jonathan	Chief Operating Officer	Mar 01 '24	Option Exercise	0.61	83,321	51,242	268,957	Mar 05 05:16 PM
Cheng Andrew	President and CEO	Jan 02 '24	Option Exercise	0.61	40,000	24,600	590,911	Jan 03 05:00 PM
Young Jonathan	Chief Operating Officer	Dec 27 '23	Option Exercise	6.36	5,414	34,433	190,545	Dec 29 08:30 PM
Young Jonathan	Chief Operating Officer	Dec 27 '23	Sale	24.00	5,414	129,936	185,131	Dec 29 08:30 PM
Cheng Andrew	President and CEO	Dec 14 '23	Sale	20.76	1,628	33,797	550,911	Dec 18 08:37 PM
White William Richard	Chief Financial Officer	Dec 14 '23	Sale	20.76	611	12,684	50,354	Dec 18 08:40 PM
Yale Catriona	Chief Development Officer	Dec 14 '23	Sale	20.76	597	12,394	77,910	Dec 18 08:49 PM
Young Jonathan	Chief Operating Officer	Dec 14 '23	Sale	20.76	543	11,273	185,131	Dec 18 08:39 PM
Rolph Timothy	Chief Scientific Officer	Dec 14 '23	Sale	20.76	514	10,671	182,672	Dec 18 08:29 PM
Cheng Andrew	President and CEO	Dec 11 '23	Option Exercise	6.36	7,405	47,096	559,944	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 11 '23	Sale	20.02	7,405	148,273	552,539	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 08 '23	Option Exercise	6.36	12,873	81,872	473,871	Dec 11 08:59 PM
Graham G. Walmsley	Director	Dec 08 '23	Buy	19.83	100,000	1,982,940	800,000	Dec 11 09:06 PM
Cheng Andrew	President and CEO	Dec 08 '23	Sale	20.01	12,873	257,571	460,998	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 07 '23	Option Exercise	6.36	6,700	42,612	467,698	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 07 '23	Sale	20.02	6,700	134,125	460,998	Dec 11 08:59 PM
Graham G. Walmsley	Director	Dec 01 '23	Buy	16.99	50,000	849,730	700,000	Dec 05 08:37 AM
Graham G. Walmsley	Director	Nov 30 '23	Buy	16.90	50,000	844,835	650,000	Dec 05 08:37 AM
Young Jonathan	Chief Operating Officer	Nov 17 '23	Sale	14.68	30,000	440,259	153,177	Nov 21 05:30 PM
Cheng Andrew	President and CEO	Oct 02 '23	Option Exercise	6.36	25,000	159,000	485,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02 '23	Option Exercise	21.10	490	10,339	183,667	Oct 04 08:33 PM
Cheng Andrew	President and CEO	Oct 02 '23	Sale	47.91	25,000	1,197,827	460,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02 '23	Sale	51.10	490	25,039	183,177	Oct 04 08:33 PM
Yale Catriona	Chief Development Officer	Sep 21 '23	Option Exercise	6.36	5,000	31,800	51,010	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 21 '23	Sale	48.07	5,000	240,356	46,010	Sep 25 08:31 PM
Graham G. Walmsley	Director	Sep 19 '23	Buy	26.00	400,000	10,400,000	400,000	May 23 09:55 PM
Cheng Andrew	President and CEO	Sep 13 '23	Sale	50.34	1,682	84,672	460,998	Sep 25 08:36 PM
White William Richard	Chief Financial Officer	Sep 13 '23	Sale	50.34	632	31,815	18,468	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 13 '23	Sale	50.34	617	31,060	46,010	Sep 25 08:31 PM
Young Jonathan	Chief Operating Officer	Sep 13 '23	Sale	50.34	562	28,291	183,177	Sep 25 08:28 PM
Rolph Timothy	Chief Scientific Officer	Sep 13 '23	Sale	50.34	531	26,731	150,689	Sep 25 08:30 PM
Cheng Andrew	President and CEO	Sep 01 '23	Option Exercise	6.36	25,000	159,000	487,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Sep 01 '23	Sale	49.77	25,000	1,244,248	462,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Aug 30 '23	Option Exercise	0.61	15,000	9,225	462,680	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28 '23	Option Exercise	6.36	5,745	36,538	52,372	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28 '23	Sale	49.99	5,745	287,191	46,627	Aug 30 07:04 PM
Graham G. Walmsley	Director	Aug 08 '23	Buy	42.06	25,000	1,051,475	600,000	Aug 10 04:46 PM
Cheng Andrew	President and CEO	Aug 01 '23	Option Exercise	6.36	25,000	159,000	472,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Aug 01 '23	Buy	43.26	25,000	1,081,525	575,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Aug 01 '23	Sale	43.15	25,000	1,078,867	447,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Jul 28 '23	Buy	42.69	30,000	1,280,709	550,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Jul 03 '23	Option Exercise	6.36	25,000	159,000	472,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jul 03 '23	Sale	44.88	25,000	1,122,041	447,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jun 27 '23	Option Exercise	0.61	40,000	24,600	447,680	Jun 27 07:12 PM
Yale Catriona	Chief Development Officer	Jun 23 '23	Sale	50.76	11,000	558,360	46,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 22 '23	Sale	52.18	11,000	573,935	57,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 21 '23	Sale	52.26	11,349	593,095	68,627	Jun 23 08:06 PM
White William Richard	Chief Financial Officer	Jun 20 '23	Option Exercise	7.01	17,500	122,658	39,877	Jun 22 05:20 PM
White William Richard	Chief Financial Officer	Jun 20 '23	Sale	55.00	20,777	1,142,735	19,100	Jun 22 05:20 PM
Heyman Tomas J.	Director	Jun 16 '23	Option Exercise	25.04	26,000	651,040	26,000	Jun 21 05:54 PM
Henderson Jane	Director	Jun 16 '23	Option Exercise	7.01	40,000	280,400	40,000	Jun 21 05:47 PM
Rolph Timothy	Chief Scientific Officer	Jun 16 '23	Option Exercise	0.61	40,000	24,400	229,420	Jun 21 05:46 PM
Rolph Timothy	Chief Scientific Officer	Jun 16 '23	Sale	54.78	78,200	4,284,066	151,220	Jun 21 05:46 PM
Henderson Jane	Director	Jun 16 '23	Sale	54.17	40,000	2,166,685	0	Jun 21 05:47 PM
Heyman Tomas J.	Director	Jun 16 '23	Sale	54.67	26,000	1,421,529	0	Jun 21 05:54 PM
Cheng Andrew	President & CEO	Jun 13 '23	Sale	55.16	1,613	88,973	407,680	Jun 15 09:38 PM
White William Richard	Chief Financial Officer	Jun 13 '23	Sale	55.16	606	33,427	22,377	Jun 15 09:41 PM
Yale Catriona	Chief Development Officer	Jun 13 '23	Sale	55.16	591	32,600	79,976	Jun 15 09:29 PM
Young Jonathan	Chief Operating Officer	Jun 13 '23	Sale	55.16	538	29,676	183,739	Jun 15 09:35 PM
Rolph Timothy	Chief Scientific Officer	Jun 13 '23	Sale	55.16	509	28,076	189,420	Jun 15 09:35 PM
Cheng Andrew	President and CEO	Jun 01 '23	Option Exercise	1.46	25,000	36,459	434,293	Jun 05 06:23 PM
Cheng Andrew	President and CEO	Jun 01 '23	Sale	45.10	25,000	1,127,430	409,293	Jun 05 06:23 PM

Open in Screener

VTYX

Ventyx Biosciences Inc

May 21 • 04:00PM ET

4.74

Dollar change -0.09
Percentage change -1.86	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

VTYX Ventyx Biosciences Inc daily Stock Chart

Held by: IWM VTI VXF IWO IBB SCHA VTWO PRFZ VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-3.24	Insider Own	28.03%	Shs Outstand	59.24M	Perf Week	13.67%
Market Cap	334.17M	Forward P/E	-	EPS next Y	-2.53	Insider Trans	-0.46%	Shs Float	50.74M	Perf Month	10.23%
Income	-192.60M	PEG	-	EPS next Q	-0.58	Inst Own	79.36%	Short Float	16.57%	Perf Quarter	-5.95%
Sales	0.00M	P/S	-	EPS this Y	22.32%	Inst Trans	7.14%	Short Ratio	2.25	Perf Half Y	91.90%
Book/sh	4.35	P/B	1.09	EPS next Y	1.17%	ROA	-53.41%	Short Interest	8.41M	Perf Year	-86.30%
Cash/sh	4.29	P/C	1.10	EPS next 5Y	-	ROE	-56.76%	52W Range	1.87 - 40.58	Perf YTD	91.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-148.81%	ROI	-60.65%	52W High	-88.32%	Beta	0.60
Dividend TTM	-	Quick Ratio	22.00	Sales past 5Y	0.00%	Gross Margin	-	52W Low	154.16%	ATR (14)	0.47
Dividend Ex-Date	-	Current Ratio	22.00	EPS Y/Y TTM	-42.23%	Oper. Margin	0.00%	RSI (14)	51.71	Volatility	9.39% 10.01%
Employees	80	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.67	Target Price	9.33
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	7.64%	Payout	-	Rel Volume	0.09	Prev Close	4.83
Sales Surprise	-	EPS Surprise	8.98%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	3.74M	Price	4.74
SMA20	7.80%	SMA50	-10.83%	SMA200	-60.20%	Trades		Volume	327,182	Change	-1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$7 → $16
Mar-12-24	Upgrade	Oppenheimer	Perform → Outperform	$12
Nov-07-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$77 → $8
Nov-07-23	Downgrade	Stifel	Buy → Hold	$6
Nov-07-23	Downgrade	Oppenheimer	Outperform → Perform
Nov-07-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$46 → $6
Nov-07-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-14-23	Resumed	Credit Suisse	Outperform	$63
Mar-21-23	Initiated	Wells Fargo	Overweight	$77
Dec-19-22	Initiated	Goldman	Buy	$50
Nov-17-22	Initiated	Morgan Stanley	Overweight	$45
Sep-07-22	Initiated	Stifel	Buy	$45
Sep-01-22	Initiated	H.C. Wainwright	Buy	$36
May-09-22	Initiated	Credit Suisse	Outperform	$53
Mar-31-22	Initiated	Canaccord Genuity	Buy	$30
Feb-01-22	Initiated	Oppenheimer	Outperform	$30
Nov-15-21	Initiated	Piper Sandler	Overweight	$50
Nov-15-21	Initiated	Jefferies	Buy	$30

Show Previous Ratings

May-16-24 04:05PM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire) +18.85%
11:23AM	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise (MT Newswires)
08:00AM	Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer (GlobeNewswire)
May-13-24 09:02PM	VTYX ALERT: Top Law Firm Bleichmar Fonti & Auld LLP Is Investigating the Directors of Ventyx Biosciences, Inc. for Potential Breaches of Fiduciary Duty; Contact the Firm for More Details (Newsfile)
10:37AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:59PM	Loading…
May-09-24 08:59PM	VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
May-02-24 04:05PM	Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-30-24 12:00PM	What Makes Ventyx Biosciences (VTYX) a New Buy Stock (Zacks)
Apr-17-24 08:45AM	NASDAQ: VTYX Lawsuit Notice: Investors who lost over $100,000 with shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX) should contact the Shareholders Foundation (GlobeNewswire) -7.98%
05:45AM	Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire)
Apr-15-24 01:15PM	Investors who lost over $100,000 with Ventyx Biosciences, Inc. (NASDAQ: VTYX) between October 2021 to November 2023, should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Mar-27-24 06:20AM	Investors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire)
Mar-20-24 05:45AM	Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX (PR Newswire) -5.06%
Mar-18-24 06:02PM	Robbins LLP Urges VTYX Investors with Large Losses to Contact the Firm Before April 30, 2024, for Information About Their Rights (Business Wire)
07:29AM	Loading…
Mar-11-24 07:29AM	Ventyx Biosciences, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 30, 2024 deadline (GlobeNewswire) -18.95%
07:00AM	Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event (GlobeNewswire)
Mar-07-24 08:52AM	NodThera says inflammation drug has positive effect in Parkinsons (BioPharma Dive) +13.18%
08:00AM	Ventyx Biosciences Announces $100 Million Private Placement of Common Stock (GlobeNewswire)
Mar-06-24 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-04-24 08:00AM	Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024 (GlobeNewswire) +5.88%
Feb-27-24 04:01PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Feb-22-24 07:00AM	Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) (GlobeNewswire) +14.48%
Feb-21-24 04:09PM	Weight-Loss Drug Hype Sends Biotech Ventyxs Stock Soaring on Rivals Data (Bloomberg) +68.56%
Feb-06-24 04:05PM	Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-23-23 11:01AM	Ventyx Biosciences Inc CEO Raju Mohan Sells 58,860 Shares (GuruFocus.com)
Nov-21-23 04:05PM	Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-23 08:00AM	Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -7.17%
Nov-09-23 04:01PM	Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) -5.15%
09:35AM	Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround (Zacks)
04:20PM	Loading…
Nov-07-23 04:20PM	Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop (Investor's Business Daily) -80.62%
08:47AM	Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today? (InvestorPlace)
07:00AM	Ventyx revises TYK2 drug plans after lackluster study data (BioPharma Dive)
Nov-06-23 04:01PM	Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update (GlobeNewswire) -9.56%
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-11-23 11:37AM	Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data (Zacks) -8.87%
Oct-10-23 04:18PM	These Stocks Are Moving the Most Today: PepsiCo, Truist, Unity Software, Rivian, Electronic Arts, and More (Barrons.com) -25.93%
12:55PM	Why Shares of Ventyx Biosciences Are Dropping Tuesday (Motley Fool)
07:44AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-09-23 04:01PM	Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis (GlobeNewswire)
Oct-07-23 05:00AM	CEO Raju Mohan Sells 30,000 Shares of Ventyx Biosciences Inc (VTYX) (GuruFocus.com)
Oct-04-23 11:01PM	Insider Sell: Christopher Krueger Sells 15,000 Shares of Ventyx Biosciences Inc (VTYX) (GuruFocus.com) -5.98%
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-08-23 05:07PM	Insider Sell: CFO Martin Auster Sells 26,472 Shares of Ventyx Biosciences Inc (GuruFocus.com)
Aug-30-23 04:05PM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-15-23 07:23AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 04:01PM	Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +6.38%
Aug-03-23 04:05PM	Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Aug-02-23 04:06PM	Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-12-23 07:22AM	Daily Vickers Top Buyers & Sellers for 07/12/2023 (Argus Research) -5.95%
Jul-03-23 02:09PM	Why Shares of Ventyx Biosciences Rose Monday (Motley Fool) +22.87%
Jun-14-23 07:00AM	Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Jun-07-23 07:00AM	Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis (GlobeNewswire)
May-31-23 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-12-23 08:57AM	Q1 2023 Ventyx Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.11%
May-11-23 04:01PM	Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
May-04-23 04:05PM	Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Mar-27-23 07:12AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 11:13AM	Q4 2022 Ventyx Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.23%
08:00AM	Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-23-23 04:01PM	Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Mar-15-23 04:05PM	Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023 (GlobeNewswire)
Mar-13-23 09:02AM	Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-11-23 01:21PM	Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure (GlobeNewswire)
Feb-28-23 08:00AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-23 08:50AM	Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why (Zacks)
Feb-13-23 09:55AM	Wall Street Analysts See a 26.67% Upside in Ventyx Biosciences, Inc. (VTYX): Can the Stock Really Move This High? (Zacks)
Feb-10-23 08:50AM	Ventyx Biosciences, Inc. (VTYX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-03-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) is a Great Choice (Zacks)
Jan-26-23 09:55AM	Wall Street Analysts Think Ventyx Biosciences, Inc. (VTYX) Could Surge 38.99%: Read This Before Placing a Bet (Zacks)
08:00AM	Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day (GlobeNewswire)
Jan-25-23 08:50AM	Here's Why Momentum in Ventyx Biosciences, Inc. (VTYX) Should Keep going (Zacks)
Jan-12-23 08:00AM	Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors (GlobeNewswire)
Jan-05-23 08:00AM	Ventyx Biosciences to Host R&D Event on January 26, 2023 (GlobeNewswire)
Jan-04-23 09:55AM	Wall Street Analysts Predict a 71% Upside in Ventyx Biosciences, Inc. (VTYX): Here's What You Should Know (Zacks) +6.25%
Dec-27-22 07:11AM	Daily Vickers Top Buyers & Sellers for 12/27/2022 (Argus Research)
Dec-22-22 07:26AM	Ventyx Biosciences, Inc. (NASDAQ:VTYX) is a favorite amongst institutional investors who own 51% (Simply Wall St.)
Dec-01-22 04:05PM	Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis (GlobeNewswire)
Nov-22-22 08:00AM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-11-22 06:35PM	Rain Therapeutics and New York Times Stock See Action From Activist Investors (Barrons.com)
Nov-03-22 04:01PM	Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Oct-27-22 04:05PM	Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022 (GlobeNewswire)
09:00AM	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Oct-24-22 09:55AM	Ventyx Biosciences, Inc. (VTYX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Sep-19-22 09:31AM	10 Best-Performing Non-Energy Stocks of 2022 (Insider Monkey)
08:00AM	Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock (GlobeNewswire)
Sep-16-22 07:16PM	Why Ventyx Biosciences Zoomed Nearly 60% Higher This Week (Motley Fool)
Sep-14-22 02:01PM	Bristol Myers Squibb Shakes Up Key Biotech Battleground (TheStreet.com) +9.01%
Aug-29-22 04:05PM	Ventyx Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-16-22 03:52PM	This Inflammatory Disease Focused Stock Is Well Positioned For $12B Crohn's Disease Market (Benzinga) +31.99%
Aug-15-22 04:05PM	Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
04:01PM	Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958 (GlobeNewswire)
Aug-11-22 04:05PM	Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Jun-30-22 08:43AM	We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-29-22 08:00AM	Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735 (GlobeNewswire)
Jun-01-22 08:00AM	Ventyx Biosciences to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-12-22 04:01PM	Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) +7.79%
May-09-22 08:00AM	Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer (GlobeNewswire) -9.12%
May-05-22 04:05PM	Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022 (GlobeNewswire)
Apr-20-22 10:16AM	Thomas Steyers Farallon Capital is Buying These 10 Stocks (Insider Monkey) +5.41%

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mohan Raju	CEO AND PRESIDENT	Apr 02 '24	Sale	5.40	4,312	23,299	1,578,250	Apr 03 07:32 PM
Krueger Christopher W	CHIEF BUSINESS OFFICER	Apr 02 '24	Sale	5.40	1,651	8,921	284,999	Apr 03 07:37 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Apr 02 '24	Sale	5.40	1,651	8,921	264,998	Apr 03 07:33 PM
Auster Martin	CHIEF FINANCIAL OFFICER	Apr 02 '24	Sale	5.40	1,405	7,592	24,303	Apr 03 07:30 PM
Krueger Christopher W	CHIEF BUSINESS OFFICER	Mar 28 '24	Option Exercise	0.00	4,531	0	286,650	Mar 29 06:15 PM
Auster Martin	CHIEF FINANCIAL OFFICER	Mar 28 '24	Option Exercise	0.00	4,531	0	25,708	Mar 29 06:12 PM
Mohan Raju	CEO AND PRESIDENT	Mar 28 '24	Option Exercise	0.00	11,843	0	1,582,562	Mar 29 06:09 PM
Nuss John	CHIEF SCIENTIFIC OFFICER	Mar 28 '24	Option Exercise	0.00	4,531	0	266,649	Mar 29 06:07 PM
Mohan Raju	CEO and President	Dec 20 '23	Sale	2.12	58,860	124,660	1,570,719	Dec 21 08:10 PM
Nuss John	Chief Scientific Officer	Dec 20 '23	Sale	2.12	17,628	37,334	262,118	Dec 21 08:14 PM
Krueger Christopher W	Chief Business Officer	Dec 20 '23	Sale	2.12	5,293	11,210	282,119	Dec 21 08:12 PM
Krueger Christopher W	Chief Business Officer	Dec 17 '23	Option Exercise	0.00	10,479	0	287,412	Dec 19 05:25 PM
Nuss John	Chief Scientific Officer	Dec 17 '23	Option Exercise	0.00	34,931	0	279,746	Dec 19 05:27 PM
Mohan Raju	CEO and President	Dec 17 '23	Option Exercise	0.00	116,668	0	1,629,579	Dec 19 05:30 PM
NSV Partners III LP	10% Owner	Oct 09 '23	Sale	30.03	49,152	1,475,858	8,439,635	Oct 11 04:21 PM
Subramaniam Somu	Director	Oct 09 '23	Sale	30.03	49,152	1,475,858	8,439,635	Oct 11 04:18 PM
Mohan Raju	Chief Executive Officer	Oct 05 '23	Option Exercise	8.04	30,000	241,200	1,542,911	Oct 06 07:16 PM
Mohan Raju	Chief Executive Officer	Oct 05 '23	Sale	29.11	30,000	873,231	1,512,911	Oct 06 07:16 PM
Krueger Christopher W	Chief Business Officer	Oct 03 '23	Option Exercise	8.04	15,000	120,600	291,548	Oct 04 07:33 PM
Nuss John	Chief Scientific Officer	Oct 03 '23	Option Exercise	3.35	10,000	33,542	254,815	Oct 04 07:26 PM
Krueger Christopher W	Chief Business Officer	Oct 03 '23	Sale	29.98	15,000	449,699	276,548	Oct 04 07:33 PM
Nuss John	Chief Scientific Officer	Oct 03 '23	Sale	29.99	10,000	299,933	244,815	Oct 04 07:26 PM
Subramaniam Somu	Director	Sep 18 '23	Sale	37.81	56,665	2,142,634	8,488,787	Sep 20 07:19 PM
NSV Partners III LP	10% Owner	Sep 18 '23	Sale	37.81	56,665	2,142,634	8,488,787	Sep 20 07:16 PM
Mohan Raju	Chief Executive Officer	Sep 05 '23	Option Exercise	8.04	30,000	241,200	1,542,911	Sep 07 04:25 PM
Krueger Christopher W	Chief Business Officer	Sep 05 '23	Option Exercise	8.04	15,000	120,600	291,548	Sep 07 04:28 PM
Nuss John	Chief Scientific Officer	Sep 05 '23	Option Exercise	0.20	10,000	2,000	254,815	Sep 07 04:21 PM
Mohan Raju	Chief Executive Officer	Sep 05 '23	Sale	32.61	30,000	978,343	1,512,911	Sep 07 04:25 PM
Auster Martin	Chief Financial Officer	Sep 05 '23	Sale	32.61	26,472	863,334	21,177	Sep 07 04:31 PM
Krueger Christopher W	Chief Business Officer	Sep 05 '23	Sale	32.61	15,000	489,109	276,548	Sep 07 04:28 PM
Nuss John	Chief Scientific Officer	Sep 05 '23	Sale	32.60	10,000	325,960	244,815	Sep 07 04:21 PM
Sandborn William J.	See Remarks	Aug 31 '23	Option Exercise	14.85	11,900	176,715	60,289	Sep 01 04:45 PM
Sandborn William J.	See Remarks	Aug 31 '23	Sale	33.64	11,900	400,354	48,389	Sep 01 04:45 PM
Sandborn William J.	See Remarks	Aug 08 '23	Sale	32.86	3,494	114,810	24,194	Aug 08 06:57 PM
Mohan Raju	Chief Executive Officer	Aug 07 '23	Option Exercise	8.04	30,000	241,200	1,542,911	Aug 08 06:54 PM
Mohan Raju	Chief Executive Officer	Aug 07 '23	Sale	33.52	30,000	1,005,570	1,512,911	Aug 08 06:54 PM
Krueger Christopher W	Chief Business Officer	Aug 03 '23	Option Exercise	8.04	15,000	120,600	291,548	Aug 04 06:06 PM
Nuss John	Chief Scientific Officer	Aug 03 '23	Option Exercise	0.20	10,000	2,000	254,815	Aug 04 06:08 PM
Krueger Christopher W	Chief Business Officer	Aug 03 '23	Sale	35.59	15,000	533,797	276,548	Aug 04 06:06 PM
Nuss John	Chief Scientific Officer	Aug 03 '23	Sale	35.60	10,000	355,986	244,815	Aug 04 06:08 PM
Sandborn William J.	See Remarks	Jul 31 '23	Option Exercise	14.85	11,900	176,715	60,289	Aug 01 04:21 PM
Sandborn William J.	See Remarks	Jul 31 '23	Sale	37.16	11,900	442,261	48,389	Aug 01 04:21 PM
NSV Partners III LP	10% Owner	Jul 31 '23	Sale	37.59	10,803	406,035	8,545,452	Aug 01 05:43 PM
Subramaniam Somu	Director	Jul 31 '23	Sale	37.59	10,803	406,035	8,545,452	Aug 01 05:44 PM
Subramaniam Somu	Director	Jul 28 '23	Sale	37.53	611	22,933	8,556,255	Aug 01 05:44 PM
NSV Partners III LP	10% Owner	Jul 28 '23	Sale	37.53	611	22,933	8,556,255	Aug 01 05:43 PM
Auster Martin	Chief Financial Officer	Jul 25 '23	Option Exercise	3.45	28,000	96,600	75,649	Jul 26 06:51 PM
Auster Martin	Chief Financial Officer	Jul 25 '23	Sale	35.54	28,000	995,044	47,649	Jul 26 06:51 PM
Subramaniam Somu	Director	Jul 12 '23	Sale	37.62	3,275	123,219	8,556,866	Jul 13 09:25 PM
NSV Partners III LP	10% Owner	Jul 12 '23	Sale	37.62	3,275	123,219	8,556,866	Jul 13 09:26 PM
NSV Partners III LP	10% Owner	Jul 11 '23	Sale	37.54	28,646	1,075,411	8,560,141	Jul 13 09:26 PM
Subramaniam Somu	Director	Jul 11 '23	Sale	37.54	28,646	1,075,411	8,560,141	Jul 13 09:25 PM
Subramaniam Somu	Director	Jul 07 '23	Sale	35.23	100,000	3,523,057	9,552,965	Jul 11 09:15 PM
NSV Partners III LP	10% Owner	Jul 07 '23	Sale	35.23	100,000	3,523,057	9,552,965	Jul 11 09:13 PM
Mohan Raju	Chief Executive Officer	Jul 05 '23	Option Exercise	8.04	29,785	239,471	1,542,911	Jul 05 08:23 PM
Mohan Raju	Chief Executive Officer	Jul 05 '23	Sale	38.37	30,000	1,151,227	1,512,911	Jul 05 08:23 PM
Sandborn William J.	See Remarks	Jul 03 '23	Option Exercise	14.85	11,900	176,715	60,289	Jul 05 08:16 PM
Krueger Christopher W	Chief Business Officer	Jul 03 '23	Option Exercise	0.77	15,000	11,538	291,548	Jul 05 08:18 PM
Nuss John	Chief Scientific Officer	Jul 03 '23	Option Exercise	0.20	20,000	4,000	264,815	Jul 05 08:20 PM
NSV Partners III LP	10% Owner	Jul 03 '23	Sale	39.00	134,080	5,229,698	9,652,965	Jul 06 06:25 PM
Subramaniam Somu	Director	Jul 03 '23	Sale	39.00	134,080	5,229,698	9,652,965	Jul 06 06:21 PM
Nuss John	Chief Scientific Officer	Jul 03 '23	Sale	39.58	20,000	791,637	244,815	Jul 05 08:20 PM
Krueger Christopher W	Chief Business Officer	Jul 03 '23	Sale	39.22	15,000	588,343	276,548	Jul 05 08:18 PM
Sandborn William J.	See Remarks	Jul 03 '23	Sale	40.00	11,900	476,014	48,389	Jul 05 08:16 PM
Sandborn William J.	See Remarks	Jul 03 '23	Sale	40.00	3,487	139,480	27,688	Jul 05 08:16 PM
Sandborn William J.	See Remarks	Jun 23 '23	Option Exercise	0.20	10,790	2,158	59,179	Jun 27 06:01 PM
Sandborn William J.	See Remarks	Jun 23 '23	Sale	32.70	10,790	352,844	48,389	Jun 27 06:01 PM
Sandborn William J.	See Remarks	Jun 15 '23	Sale	34.15	3,487	119,092	31,175	Jun 16 09:16 PM
NSV Partners III LP	10% Owner	Jun 14 '23	Sale	35.08	50,000	1,753,785	9,787,045	Jun 16 07:15 PM
Subramaniam Somu	Director	Jun 14 '23	Sale	35.08	50,000	1,753,785	9,787,045	Jun 16 07:21 PM
NSV Partners III LP	10% Owner	Jun 07 '23	Sale	35.66	35,872	1,279,108	9,837,045	Jun 08 09:47 PM
Subramaniam Somu	Director	Jun 07 '23	Sale	35.66	35,872	1,279,108	9,837,045	Jun 08 09:50 PM
Auster Martin	Chief Financial Officer	Jun 06 '23	Option Exercise	3.45	28,000	96,600	75,649	Jun 07 06:54 PM
Auster Martin	Chief Financial Officer	Jun 06 '23	Sale	34.64	28,000	969,963	47,649	Jun 07 06:54 PM
Subramaniam Somu	Director	Jun 06 '23	Sale	35.00	4,128	144,481	9,872,917	Jun 08 09:50 PM
NSV Partners III LP	10% Owner	Jun 06 '23	Sale	35.00	4,128	144,481	9,872,917	Jun 08 09:47 PM
Krueger Christopher W	Chief Business Officer	Jun 05 '23	Option Exercise	2.66	15,000	39,973	291,548	Jun 06 07:19 PM
Nuss John	Chief Scientific Officer	Jun 05 '23	Option Exercise	0.20	10,000	2,000	254,815	Jun 07 06:59 PM
Mohan Raju	Chief Executive Officer	Jun 05 '23	Sale	34.36	30,000	1,030,652	1,513,126	Jun 06 07:18 PM
Krueger Christopher W	Chief Business Officer	Jun 05 '23	Sale	34.36	15,000	515,379	276,548	Jun 06 07:19 PM
Nuss John	Chief Scientific Officer	Jun 05 '23	Sale	34.35	10,000	343,467	244,815	Jun 07 06:59 PM
Sandborn William J.	See Remarks	May 31 '23	Option Exercise	0.20	10,629	2,126	59,018	Jun 01 05:53 PM
Sandborn William J.	See Remarks	May 31 '23	Sale	34.26	10,629	364,155	48,389	Jun 01 05:53 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

IRON

Disc Medicine Inc

AKRO

Akero Therapeutics Inc

VTYX

Ventyx Biosciences Inc

Upgrade your FINVIZ experience